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Abstract: Lung cancer is the most common cancer in the world and pain is its most common symptom. Pain can be brought about 
by several different causes including local effects of the tumor, regional or distant spread of the tumor, or from anti-cancer treatment. 
Patients with lung cancer experience more symptom distress than patients with other types of cancer. Symptoms such as pain may be 
associated with worsening of other symptoms and may affect quality of life. Pain management adheres to the principles set out by the 
World Health Organization’s analgesic ladder along with adjuvant analgesics. As pain can be caused by multiple factors, its treatment 
requires pharmacological and non-pharmacological measures from a multidisciplinary team linked in with specialist palliative pain 
management. This review article examines pain management in lung cancer.
Keywords: analgesia, lung cancer, pain management
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Introduction
Lung cancer is the most common cancer in the world 
with 1.61 million new cases diagnosed every year.1 
Pain is the most common symptom in cancer patients 
in general as it also is for lung cancer specifically.2 
The majority of patients with lung cancer have an 
advanced stage of the disease at clinical presentation. 
Symptoms may result from local effects of tumor, from 
regional or distant spread, or from distant effects not 
related to metastases (paraneoplastic syndromes).
Patients with lung cancer experience more 
symptom distress than patients with other types of 
cancers.3 Symptoms such as pain may be associated 
with worsening of other symptoms including 
depression and fatigue,4 and may affect quality of 
life.5 It has been demonstrated that early palliative care 
intervention, including good symptom management, 
improves quality of life and may increase survival.6 
Pain resulting from lung cancer can be classified by 
two methods: either by the type of pain or according 
to the origin of the pain. The location or origin of the 
pain may determine the type of pain experienced. 
Pain can also be affected by the histological type 
and biological behavior of the lung cancer present.7 
Pain in patients with lung cancer can be differentiated 
according to its origin, namely intra-thoracic or extra-
thoracic, the latter of which may be the consequence 
of cancer complications.
pain
Definition
Pain is defined as an ‘unpleasant sensory or emotional 
experience associated with actual or potential tissue 
damage, or described in terms of such damage.’8 
It impacts greatly upon physical and psychosocial 
functioning. Pain is often multi-factorial in origin; 
therefore it follows that its management needs to be 
multi-disciplinary in order to address each aspect 
of pain.
Incidence
Cancer pain can be characterized by two syndromes, 
namely acute pain and chronic pain syndromes. The 
acute cancer pain syndrome is usually due to a definable 
acute injury or illness.9 This could be secondary to 
cancer disease events such as hemorrhage into a tumor, 
bone pain secondary to a pathological fracture, visceral 
pain from acute intestinal obstruction or perforation of 
a viscous. Acute cancer pain has a definite onset and 
its duration is limited and predictable. It is associated 
with clinical signs of sympathetic over activity such 
as tachycardia, hypertension, sweating, pupillary 
dilatation and pallor.
Chronic cancer pain can result from the same 
causes as acute pain but is differentiated by its 
longevity. In the UK, this is termed background pain 
and is defined as ‘constant or continuous pain of long 
duration’.10 Background pain refers to pain persisting 
for more than 12 hours per day. It often has a gradual 
or ill-defined onset with the potential to progress in 
severity. It is estimated that approximately 75% of 
cancer patients live with chronic pain, this pain is 
secondary to nociceptive or neuropathic syndromes 
which represent direct effects of the cancer.11 Chronic 
pain must be approached differently with the dual 
aim of relieving the pain as well as preventing further 
recurrences of pain.
Many patients develop flares of pain, despite 
reporting acceptable analgesia for the majority 
of the day. The term given to this type of pain is 
breakthrough cancer pain (BTCP). Breakthrough 
pain has been defined as a ‘transitory exacerbation of 
pain in patients receiving chronic opioid therapy with 
acceptable analgesia.’12 Patients may be severely 
limited by breakthrough pain, which impacts greatly 
upon patients’ quality of life and causes psychological 
burden.13,14 Breakthrough cancer pain can either have 
rapid or gradual onset and can vary in duration from a 
few minutes to a few hours. BTCP may be spontaneous 
in onset with no known precipitant, or may be incident 
in nature with an identifiable precipitant, such as 
movement, or other triggers specific to the patient.15 
The transitory nature of this pain poses challenges 
for management. Analgesia for breakthrough cancer 
pain therefore is required to mimic the profile of these 
episodes with rapid onset and short duration.
Pathophysiology
Cancer cells and the subsequent effects of tissue dam-
age cause the production of noxious substances which 
stimulate the peripheral nerve endings of the C and 
A-delta primary afferent fibers. Stimulation of these 
fibers results in the lowering of activation thresholds, 
the recruitment of quiescent nociceptors, and the acti-
vation of NMDA-receptor-channel complex leading 
to dorsal horn sensitization. This process results in 
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pain generation and maintenance. The changes in the 
dorsal horn therefore need to be targeted to relieve 
pain and prevent pain recurrence.16
Physiological pain is termed nociceptive pain. This 
is due to stimulation of the sensory nociceptors, located 
in tissues, when damaged. Somatic pain, from the skin 
and superficial structures, is usually well localized 
and can be described as aching, sharp, throbbing or 
pressure-like. Visceral pain, from deep structures, is 
less well localized. It often presents as referred pain 
and may be described as a deep, aching pain.16
Neuropathic pain is caused by peripheral or 
central nervous system injury. It is often described 
as burning, shooting and may be associated with 
altered sensation. Neuropathic pain is associated 
with a loss of opioid receptors in sensory afferents 
and an increased release of glutamate (a neuro-
excitatory amino-acid) in the dorsal horn. Activation 
of glial cells, neuroma formation, increase in sodium 
channels, and calcium channel activation results in 
sensitization of the dorsal horn and higher centers. 
This resultant hyper excitability causes spontaneous 
pain, hyperalgesia, and allodynia in areas adjacent 
to the nerve damage. An injured sensory nerve may 
produce absent or abnormal sensation. These changes 
thus lead to a variable response to opioids.2,17
Causes of pain in advanced lung cancer
The three main causes of pain in patients with advanced 
lung cancer are skeletal metastatic disease (34%), 
pancoast tumor (31%) and chest wall disease (21%).18
In order to manage pain in lung cancer patients it 
is essential to understand and use general  principles 
of pain management. The analgesic options include 
opioids which may be combined with adjuvant 
analgesics for optimal palliation of pain. Pain 
refractory to general management may require 
 specialist skills and techniques.
principles of pain Management
The World Health Organization’s (WHO) Analgesic 
Ladder for Cancer Pain Relief provides a stepwise 
approach to managing pain in patients with cancer.19 
The WHO analgesic ladder is simple to follow and 
applicable to all pain, regardless of its etiology. Step 1 
advises the use of paracetamol or a non-steroidal anti-
 inflammatory drug. If pain is not satisfactorily con-
trolled, it is appropriate to move to Step 2 Analgesia 
which includes the use of weak opioids, usually codeine. 
In practice, patients with severe pain usually need 
Step 3 Analgesia, the use of strong opioids. Morphine 
is the usual first-line Step 3 opioid however there are 
many alternatives to morphine now.20 At any step, in the 
analgesic ladder adjuvant analgesics can be used.
There have been concerns about the life shortening 
effects of opioids when considering administration of 
these drugs for symptom alleviation at end of life. One 
study has shown that there was no significant survival 
difference between those patients who were taking 
opioids and those who were not.21 It also showed that 
patients with lung metastases required lower doses of 
opioids, compared to patients with spinal metastases. 
Increased age was also associated with decreasing 
opioid doses.
Commonly used analgesics and doses are given in 
Table 1.
Opioids
Morphine is the usual first line strong opioid employed 
to manage cancer pain. Morphine’s effects are 
mediated by specific opioid receptors both within the 
central nervous system and peripherally. Morphine’s 
main peripheral action is on smooth muscle. However, 
in the presence of inflammation, the normally silent 
peripheral receptors become activated.22 Morphine is 
mostly metabolized in the liver via glucoronidation 
yielding the metabolites morphine-6-glucuronide 
(M6G) and morphine-3-glucuronide (M3G). M6G 
has a greater analgesic potency than morphine itself 
while M3G is a non-analgesic. Both glucuronides 
accumulate if renal failure occurs, resulting in 
prolonged duration of action and greatly increased 
risk of severe side effects, namely neurotoxicity and 
respiratory depression.
Opioids can be administered orally, intravenously, 
subcutaneously, sublingually, intrathecally, and topically 
depending on its indication and available routes for 
administration. It has immediate release and sustained 
release preparations for ease of use. Both immediate 
and sustained release preparations have equivalent 
analgesic effects.23,24 When opioids are prescribed, a 
laxative should be prescribed concurrently to alleviate 
the onset of opioid induced constipation (OIC).
The main route of administration of morphine 
is orally. Ideally two types of formulation are 
required: normal release (for dose titration initially 
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and breakthrough analgesia) and modified release 
(for maintenance therapy).20 The starting dose will be 
determined by previous analgesic treatment.
Morphine, like other strong opioids is titrated until 
the desired analgesic benefit is achieved.
Oxycodone
Oxycodone hydrochloride is a semi-synthetic con-
gener of morphine. It may be useful in patients with 
renal failure due to the lack of detectable clinically 
relevant active metabolites. The equi-analgesic dose 
of oral oxycodone is between half and two-thirds that 
of oral morphine.25
Hydromorphone
Hydromorphone is a semi-synthetic opioid agonist 
with a rapid onset and shorter duration of action 
than morphine. It is a potent mu-selective agonist 
similar to morphine and between 5 and 10 times as 
potent.20 There are no major differences between 
hydromorphone and morphine concerning efficacy 
and adverse effects when comparing equivalent 
dosages.26
Methadone
Methadone is a synthetic opioid with mixed properties. 
It is a mu opioid receptor agonist, possibly a delta 
opioid receptor agonist, an NMDA-receptor channel 
blocker, and a presynaptic blocker of serotonin 
re-uptake. It has no known active metabolites, 
low tolerance development, and long duration of 
analgesia.27 Its half-life is long and unpredictable 
and therefore should be prescribed under specialist 
advice.
Fentanyl
Fentanyl is a pure mu agonist. It is generally not 
administered orally due to it undergoing exten-
sive first-pass metabolism. Preparations which 
are absorbed through the oral or nasal mucosa are, 
Table 1. Common analgesics for pain in patients with lung cancer.
Analgesic name Typical starting dose (oral) Maximum dosage
Acetaminophen Paracetamol 1 g qds 4 g daily
Non-steroidal anti-inflammatory Ibuprofen 400 mg tds 2.4 g daily
weak opioid Codeine phosphate 30 mg–60 mg qds 240 mg daily
Strong opioid 
(Dose requirements should be  
individually titrated according to  
pain, analgesic response to pain  
and side effects)
Morphine 10 mg every 4–6 hours for  
opioid naïve patients
Oxycodone 5 mg every 4–6 hours
Hydromorphone 1.3 mg every 4–6 hours 
(immediate release 
hydromorphone capsules  
are only available in strengths  
of 1.3 mg and 2.6 mg)
(Modified release 
hydromorphone capsules are 
only available in strengths of 
2 mg, 4 mg, 8 mg, 16 mg  
and 24 mg)
Tricyclic antidepressants Amitriptyline 10 mg nocte 75 mg (neuropathic pain)
Nortriptyline 10 mg nocte 75 mg (neuropathic pain)
Imipramine 10 mg daily 75 mg (neuropathic pain)
Clomipramine 10 mg daily 75 mg (neuropathic pain)
Serotonin and noradrenaline 
reuptake inhibitor
Duloxetine 60 mg od 120 mg
Selective serotonin reuptake 
inhibitors
Citalopram 20 mg 60 mg
Alpha—2—adrenergic agonists Clonidine 50 mcg bd 150 mcg
Anticonvulsants Gabapentin 300 mg gradually titrated  
upwards, given in divided  
doses, usually tds
3.6 g
Pregabalin 75 mg bd 300 mg
Carbamazepine 100 mg od 1.6 g
Clonazepam 500 mcg nocte 4–8 mg
NMDA receptor antagonists Ketamine 10 mg qds 400 mg
Corticosteroid Dexamethasone 4–8 mg od varies according to indication
Abbreviations: od, once daily; bd, twice daily; tds, three times daily; qds, four times daily; nocte, night-time.
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however, available. It is lipophilic which facilitates 
absorption through the skin. Trans-dermal administra-
tion is useful for patients with stable pain and stable 
opioid requirements. Fentanyl lacks active metabo-
lites and is useful in patients with renal failure.
Opioids for breakthrough cancer pain
In BTCP which is gradual onset (approximately 
30 minutes) and lasts longer than one hour, standard 
immediate release opioid preparations (eg, oral 
morphine) are sufficient. In BTCP which is rapid 
onset (5–10 minutes) and short duration (less than 
60 minutes), fentanyl is a good choice of opioid. A num-
ber of preparations exist which are either absorbed 
through the nasal or oral mucosa. Due to it being 
lipophilic, it is rapidly absorbed through the oral or 
nasal mucosa enabling it to have a quick onset of action. 
Fentanyl preparations specifically developed for BTCP 
exist in several preparations including a lozenge, a sol-
uble film, a buccal tablet, and a nasal spray. There is a 
lack of evidence comparing fentanyl products for BTCP 
and there is no consensus on the correct dose when pre-
scribing rapid acting opioids for BTCP.28 Each fentanyl 
product should be titrated to the most effective dose that 
provides adequate analgesia with minimal side effects.
Opioid induced constipation
One of the most commonly encountered side effects 
from opioids is OIC. A meta-analysis of 11 placebo-
controlled randomized studies in non-malignant pain 
showed that OIC affects an average of 41% patients 
taking an oral opioid for up to eight weeks.29 The 
cause of OIC is multifactorial. Opioids interfere with 
normal gastrointestinal motility by delaying transit, 
stimulating non-propulsive motility, segmentation 
and tone, and stimulation of sphincters such as the 
pylorus and ileocaecal sphincter through their effect 
on enteric neurons. Opioids also stimulate the absorp-
tion of fluids, mainly by delayed transit and by stimu-
lating mucosal sensory receptors that activate a reflex 
arc that facilitates further fluid absorption.30–32
Some opioids are less constipating than others. 
Tapentadol hydrochloride is a µ-opioid agonist that 
also inhibits norepinephrine reuptake.33 It has been 
shown to have a more favorable gastrointestinal side 
effect profile than the classic µ-opioid receptor agonist 
oxycodone.34 Fentanyl is also less constipating than 
equi-analgesic doses of morphine. Transdermal fentanyl 
was associated with a significantly lower use of 
laxatives compared to oral morphine in one study.35 
Another study comparing transdermal fentanyl with 
sustained release oral morphine demonstrated a 
patient preference for transdermal fentanyl. The rea-
sons given by the patients included better analgesia, 
less constipation, and an enhanced quality of life with 
transdermal fentanyl.36
Most patients taking an opioid require a laxative 
to counteract the OIC. These include osmotic and 
stimulant laxatives. An adjunct to existing laxative 
therapy for patients with OIC receiving palliative 
care is methylnaltrexone. Methylnaltrexone is a 
quaternary ammonium derivative of naltrexone, an 
opioid antagonist similar to naloxone, but it is less 
lipid soluble, so less likely to cross the blood-brain 
barrier. Methylnaltrexone blocks acute morphine-
induced delay in orocecal transit time without affecting 
analgesia or causing central opioid withdrawal 
symptoms.37 It is administered as a subcutaneous 
injection and contraindicated in cases of known or 
suspected gastrointestinal obstruction.
Naloxone itself has a low systemic bioavailability. 
The oral fixed-ratio combination of oxycodone 
prolonged-release and naloxone prolonged-release has 
been shown to be superior to oxycodone prolonged-
release alone, offering effective analgesia while 
significantly improving OIC. One study demonstrated 
a significant improvement in Bowel Function Index 
scores with the oral fixed-ratio combination of 
oxycodone prolonged-release and naloxone-prolonged 
release, without compromising the analgesic efficacy 
of the oxycodone component.38
Opioid toxicity
There is no “top dose” of morphine or other strong 
opioids; however the dose limits may be hit by 
opioid related side-effects. When patients start to 
demonstrate symptoms of opioid related toxicity 
(vivid dreams, nightmares, pseudohallucinations 
(shadows at the periphery of the field of vision), 
hallucinations, somnolence, cognitive impairment 
etc.) then they have reached the limits of tolerance to 
an individual opioid. In such situations, if analgesia 
has been achieved, the dose of strong opioid can be 
reduced. If analgesia has not been achieved, then often 
patients are switched from one opioid to another. The 
rationale for this practice is that different opioids work 
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on different subsets of opioid receptors or there may 
be a genetic predisposition to different opioids. In 
such cases, following an opioid switch, analgesia may 
be achieved at a lower equi-analgesic level or side-
effects of the new opioid may be better tolerated.39
Adjuvant analgesics
Adjuvant analgesics are drugs whose primary 
purpose is not analgesia, but have analgesic benefits. 
In practical terms, the majority of common adjuvant 
analgesics are used for pain management. Adjuvant 
analgesics are often first line therapy for certain types 
of pain. Antidepressant analgesics are most commonly 
prescribed for neuropathic pain.40 The majority of the 
evidence for their use is based on patients with chronic 
pain. They are thought to enhance availability of 
monoamines at synapses within neural pathways that 
are part of the descending pain modulating system. 
The most important modes of action include inhibition 
of norepinephrine reuptake, and serotonergic and 
dopaminergic effects. Early use of antidepressants 
as adjuvant analgesics is also justified when pain is 
accompanied by depression.
Tricyclic antidepressants
Tricyclic antidepressants alone or in combination 
with other adjuvant analgesics, have been shown to 
be effective in treating neuropathic pain.41 Tricyclic 
antidepressants include tertiary amines (amitriptyline) 
and secondary amines (nortriptyline and desipramine). 
Subtypes of tricyclic antidepressants inhibiting both 
serotonin and noradrenaline reuptake (amitriptyline, 
imipramine, clomipramine) have a slightly greater 
analgesic effect compared to the more selective 
inhibitors for noradrenaline reuptake (desipramine, 
nortriptyline, maprotiline). However, the newer 
secondary amines have fewer side effects. Care must 
be taken when prescribing tricyclic antidepressants 
which are contraindicated in patients with ischaemic 
heart disease and glaucoma. Caution must be exercised 
when prescribing them to patients at risk of orthostasis 
such as patients with autonomic neuropathy or 
elderly patients. Non tricyclic antidepressant drugs 
are generally better tolerated and safer to use.
Selective norepinephrine reuptake inhibitors
Serotonin norepinephrine reuptake inhibitors 
(SNRIs) have been proven to have analgesic efficacy. 
Mainly non-cancer populations of patients with 
diabetic neuropathy have been examined to ascertain 
the analgesic effects of antidepressants. This is the case 
for SNRIs including duloxetine.42 There have been no 
comparative trials within the SNRI class and there are 
no clinical trials in patients with cancer pain.
Serotonin selective reuptake inhibitors
Serotonin selective reuptake inhibitors have a 
favorable side effect profile however there is minimal 
evidence of analgesic efficacy. Studies have suggested 
benefits for paroxetine and citalopram.43,44 Studies 
have shown analgesic benefit from venlafaxine, in 
particular for painful polyneuropathy.45
Alpha—2 adrenergic agonists
Clonidine has been studied in non-malignant 
neuropathic pain, however its side effects are poorly 
tolerated in elderly patients.46 Spinally administered 
Clonidine has analgesic properties in patients with 
cancer pain and is more efficacious for neuropathic 
than nociceptive pain.47 There is less evidence for 
tizanidine which has been approved as an anti-
spasticity agent. It has been shown to have analgesic 
efficacy in myofascial pain syndrome,46 and the 
prophylaxis of chronic daily headache.48
Anticonvulsants
Anticonvulsants have been extensively studied in the 
management of neuropathic pain.49 Both gabapentin 
and pregabalin have been shown to be effective in 
neuropathic pain management. They are excreted by 
the kidneys and rarely have drug-drug interactions. 
Both are chemical analogues of GABA but do not 
act as a GABA-receptor agonist, acting instead at the 
alpha-2-delta voltage gated subunit of the calcium 
channel in the dorsal horn. Gabapentin is used for 
central and peripheral neuropathic pain.50 Pregabalin 
is also licensed for peripheral and central neuropathic 
pain and has been studied in diabetic neuropathy, post 
herpetic neuralgia, and central pain due to spinal cord 
injury.51–53
Other anticonvulsants used for analgesia include 
carbamazepine, sodium valproate, and phenytoin. 
These drugs have increased side effect profiles which 
must be kept in mind when prescribing for patients 
with cancer. Clonazepam is often used for patients 
with neuropathic pain however there is a paucity of 
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evidence to support its analgesic efficacy.54 There is 
also limited evidence of analgesic benefits from ben-
zodiazepines; however, in clinical practice their use is 
justified by the coexistence of anxiety with pain.
Other analgesics
NMDA receptor antagonists
The N-methyl-D-aspartate (NMDA) receptor is 
involved in CNS changes that underlie chronic 
pain and modulate opioid mechanisms, specifically 
tolerance.55 Ketamine acts as an NMDA antagonist and 
may be useful in some pain types, such as neuropathic 
pain.56 Ketamine is a parenteral general anesthetic 
that can be used in sub-anesthetic doses to relieve 
pain, particularly in opioid-tolerant patients.57 This 
should only be administered under specialist advice. 
The evidence for other NMDA receptor antagonists 
such as amantadine, in cancer pain, is limited.
Corticosteroids
Corticosteroids may be a useful adjunct in cancer 
pain syndromes. These include neuropathic pain, 
bone pain, headache secondary to raised intracranial 
pressure, pain secondary to organ capsule distension, 
pain due to obstruction of a hollow viscus, and 
pain secondary to lymphedema. Dexamethasone is 
commonly used due to having less mineralocorticoid 
effects and its long half-life. Other glucocorticoids 
such as prednisolone and methylprednisolone may be 
used. The side effects of steroids must be carefully 
considered when prescribing for patients with cancer 
and the lowest dose providing symptomatic relief 
should be sought.
Cannabinoids
Cannabinoids have potential therapeutic value as 
analgesics,58 and there are several clinical trials in 
progress looking at the use of sublingual cannabinoids 
in patients with cancer pain. The oro-mucosal spray 
Sativex is currently unlicensed in the UK for cancer 
pain however it is approved in some other countries 
for the treatment for neuropathic pain due to multiple 
sclerosis and as an adjunctive analgesic in patients 
with advanced cancer.59
Topical analgesics
Topical preparations of analgesics are useful in 
pain which is localized to a defined area of skin. 
Topical preparations have minimal systemic side 
effects and are well tolerated. Topical lidocaine 
plasters containing 5% lidocaine are currently licensed 
for the relief of post-herpetic neuralgia, but have been 
used in patients with cancer.40 Lidocaine can also be 
prepared as a topical cream for application under an 
occlusive dressing.60 Topical capsaicin cream is also 
used for neuropathic pain.61 Capsaicin affects the 
synthesis, storage, transport and release of substance P 
in nociceptive fibers. It comes in varying strengths, 
the stronger of which are licensed for intermittent 
application.
The high potency 8% capsaicin topical patch 
is licensed for treating patients with post herpetic 
neuralgia. It is licensed in Europe for the treatment 
of peripheral neuropathic pain in non-diabetic adults. 
In controlled trials it has demonstrated pain relief for 
up to 3 months with a single 30 minute or 60 minute 
application.62
Interventional procedures
Prior to embarking on interventional procedures, the 
likely benefits and potential risks need to be consid-
ered and compared with those of continuing with phar-
macological management. Typically interventional 
management of cancer pain does not substitute for 
other modalities but can improve pain control and 
allow for a reduction in systemic medications and 
their side effects. Where there are unacceptable side 
effects from oral or parenteral opioids, then invasive 
methods may be preferred.
Most interventional procedures involve interruption 
to or modification of nerve conduction with the aim of 
diminishing pain from a target area. The procedures 
may be considered to be non-destructive or destructive. 
In non-destructive procedures, nerve blockade or 
modulation is achieved by the deposition of reversible 
pharmacological agents. These may be given by bolus 
injection. Alternatively catheter placement allows for 
the continuous delivery of pharmacological agents. 
Placement can be adjacent to peripheral or autonomic 
nerves or placement may be in the spinal canal with the 
aim of modulating neuronal activity of the spinal cord.
Peripheral nerve blocks have a limited role in 
cancer pain management. There is no controlled trial 
evidence but case studies describe pain relief for 
short periods with the local anesthetic blockade of the 
regional nerve supply to a target area. Nerve blocks 
Simmons et al
338 Clinical Medicine Insights: Oncology 2012:6
may be useful for acute cancer pain such as intercostal 
nerve blockade for a pathological rib fracture. In order 
to prolong the analgesic effect, an infusion of local 
anesthetic adjacent to a neural plexus (eg, brachial 
plexus) or other nerves may be used.63,64
Neurolytic blockade of peripheral nerves (eg, 
intercostal neurolysis) produces short term relief of 
pain and has a median duration of 3 weeks.65 Other 
studies have reported an incidence of neuritis with 
neurolytic blockade and advise that neurolytic agents 
be limited to those with a short life expectancy.66
Neuroaxial blocks may be epidural or intrathecal. 
An epidural neuroaxial block of local anesthetic 
and steroid can provide temporary pain relief where 
a vertebral metastasis is associated with nerve 
compression. A neuroaxial saddle block can be used 
for perineal pain of somatic origin (more common 
in advanced pelvic cancer) especially where bladder 
and bowel function are already compromised. For 
patients who require prolonged analgesia, a neuroaxial 
infusion may be administered. These are considered 
for patients with advanced cancer whose pain cannot 
be controlled with systemic medication, or the use of 
systemic medication is limited by unacceptable side 
effects at doses below those required to give adequate 
pain relief. A neuroaxial infusion, either epidurally 
or intrathecally, gives good control in the majority of 
cases.67 The most effective drugs to infuse neuroaxially 
are opioids. Patients who are unresponsive to large 
doses of systemic opioids are unlikely to respond to 
spinal opioids. Other drugs that appear to be effective 
spinally include local anesthetics (Bupivacaine), 
alpha-2 agonists (Clonidine), and ziconotide. The 
procedure for inserting a neuroaxial infusion is 
undertaken in centers experienced in these specialized 
techniques and their aftercare. There are different 
neuroaxial systems ranging from percutaneous 
lines to fully implanted programmable pumps. The 
fully implanted systems carry less risk of infection 
and have lower maintenance requirements but the 
operation is more prolonged.68 Costing of neuroaxial 
infusions currently suggests that implanted systems 
are more cost effective than the percutaneous system 
after 3 months.69 There is evidence from randomized 
controlled trials of improved pain relief and less drug 
related side effects compared with medical therapy for 
fully implanted systems.70 A percutaneous catheter, 
injection portal, or fully implanted system can be 
inserted; however the device is selected according to 
individual patient factors including their prognosis.
The common causes of intrathoracic pain in 
malignancy are non-small-cell lung cancer and 
mesothelioma. This pain is often poorly localized in 
respect to the primary tumor site and in mesothelioma 
pain resulting from local infiltration of the intercostal 
nerves may become a prominent feature. Intercostal 
nerve blocks can be very effective in certain patients. 
More aggressive anesthetic interventions such as 
intraspinal analgesia or cordotomy may be required 
especially in mesothelioma.
Anterolateral cordotomy can be undertaken as a 
percutaneous or open procedure, involving interven-
tion on the side of the spinal cord opposite to that 
of the pain to ablate the spinothalamic tract fibers. 
Consequently it reduces the sensation of touch and 
temperature in addition to pain. While percutane-
ous cordotomy can only be performed in the cervical 
area, the spinothalamic fibers can be divided by open 
operation in the thoracic cord. This avoids any risk 
to respiration and to the upper limbs when the pain is 
below the waist. Patients with severe unilateral pain 
arising in the thorax or lower extremities are most 
likely to benefit from cordotomy.71 Impressive results 
have been observed in patients with chest wall pain.72 
The percutaneous technique is generally preferred; 
open cordotomy is usually reserved for patients who 
are unable to lie in the supine position or are not able 
to undergo a percutaneous procedure.73
Chest wall pain due to tumor invasion or somatic 
and neural structures can also be treated with 
rhizotomy, the segmental or multi-segmental 
destruction of the dorsal sensory roots. Rhizotomy 
is achieved by surgical section, chemical neurolysis, 
or radiofrequency ablation and can be an effective 
method of pain control with refractory localized 
pain syndromes. Chemical rhizotomy produced by 
the instillation of a neurolytic solution (eg, phenol) 
into either the epidural or intrathecal space can be 
performed at any level up to the mid-cervical regions, 
above which the spread of neurolytic agent to the 
medullary centre carries an unacceptable risk of 
cardio respiratory collapse.74
Interpleural analgesia has also been used to rapidly 
reduce acute exacerbations of cancer pain via bolus 
injection or continuous infusion. It may be tried when 
traditional neural blockade techniques fail either 
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due to inability to deliver sufficient drug volume 
due to tumor spread or altered anatomy. It has also 
been used to treat post thoracotomy pain. It should 
be noted however that currently epidural analgesia 
has emerged as the analgesic technique of choice for 
thoracotomy pain. Interpleural analgesia can be used 
as a valuable diagnostic tool for predicting the efficacy 
of permanent neurolytic block. Interpleural analgesia 
involves the administration of local anesthetic agents 
through a catheter positioned inside the pleural cavity 
to anaesthetize intercostal nerves. The mechanism of 
action appears to be diffusion across the parietal pleura. 
The catheter lies between the parietal and visceral 
pleura. Complications include pneumothorax and local 
anesthetic toxicity.75,76 Several studies, however, have 
shown limited or no improvement in analgesia with 
interpleural analgesia.77–79 Paravertebral blocks can be 
used for chest wall pain. They are typically used to 
relieve acute chest wall pain from rib fractures and to 
manage acute and chronic post thoracotomy pain.
Painful pathological fractures of vertebra that 
do not respond to the conservative treatment of 
medication or steroid epidurals can be considered for 
cemented vertebroplasty. Open studies in myeloma 
and metastatic cancers report pain relief is often 
complete in around 80% of patients.80 Percutaneous 
cementoplasty involves the injection of acrylic bone 
cement into malignant bone cavities to relieve pain 
and stabilize the bone. This is useful when treating 
bone pain from pelvic bone metastases which are not 
responding to pharmacological management.81
challenges in pain Management  
in Lung cancer
Understanding and practicing the general principles 
of pain management is paramount to managing pain 
in patients with advanced lung cancer. However there 
are disease complications specific to patients with 
lung cancer which cause severe pain and necessitate 
the use of specialist therapies or techniques to palliate 
symptoms including pain—Table 2.
Bone metastases
Approximately 20% of patients with non-small 
cell lung cancer (NSCLC) have bone metastases 
at presentation of the disease.82 In small cell lung 
cancer (SCLC) bone metastases are present in up to 
40% of patients.82 Pain caused by bone metastases 
has multiple causes. Periosteal inflammation and 
elevation is the most common mechanism of pain from 
bone metastases. Lung cancer metastases to bone are 
predominately lytic. Cancer induced bone pain has 
been shown to have unique characteristics and is a 
complex pain state. Sensory and sympathetic neurons 
are present within the bone marrow, mineralized 
bone and periosteum and all these compartments are 
affected by tumor cells. Cancer induced bone pain 
is thought to arise via the activation and ultimately 
destruction of the primary afferents within bones. 
Metastatic bone pain is therefore complex to 
manage due to nociceptive, neuropathic and visceral 
stimulation overlapping.83,84
The gold standard treatment for pain due to bone 
metastases is radiotherapy.85 Evidence suggests that 
single fraction treatment is as effective as fractionated 
therapy.86–88
If a metastasis occurs in a weight bearing bone, 
prophylactic surgical stabilization should be considered 
before a pathological fracture occurs.89 Post-operative 
radiotherapy is recommended regardless of the type 
of surgical procedure chosen for bony metastases.90
Bisphosphonates have assumed an important role 
in the treatment of patients with bone metastasis. 
They prevent bone resorption at sites of bone 
remodeling. Zoledronic acid has been shown to be 
effective treatment for bone metastasis in patients 
with lung cancer.91 It has also been shown to 
prevent skeletal related events such as pathological 
fractures, spinal cord compression, hypercal-
caemia or pain requiring surgery.92 In a study of 
NSCLC, patients treated with zoledronic acid had 
a significantly reduced incidence of skeletal related 
events.93 Intravenous radioisotope infusion can also 
be used to manage pain from bony metastases and is 
Table 2. Common causes of pain in patients with lung 
cancer.
Intra-thoracic causes  
of pain
extra-thoracic causes 
of pain
• Chest pain 
 ○ Pleural invasion 
 ○ Chest wall invasion 
 ○ Obstructive pneumonitis 
 ○ Pulmonary embolus 
 ○ Tumor invasion 
 ○ Costopleural syndrome
• Metastasis 
 ○ Bone 
 ○ Liver 
 ○ Brain 
•  Hypertrophic  
osteo-arthropathy
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especially useful in patients with widespread bony 
metastases.94
Chest pain
Chest pain is a frequent and disabling symptom, 
worsening with disease progression and is present 
in approximately 20% of patients presenting with 
lung cancer.95 Pain is frequently on the ipsilateral 
chest as the tumor site. It should be treated using the 
principles described above, however often requires 
radiotherapy to palliate pain due to destruction of 
bone or surrounding tissue.
Patients with chest wall pain due to tumor inva-
sion or neurolysis of intercostal nerves, chemical 
rhizotomy (injection of small volumes of a neuro-
lytic agent into the epidural or intrathecal space) may 
provide significant relief for a period of time. It is 
exceedingly rare for someone to need this and one 
survey reported only 16 out of 1205 patients required 
intra-spinal therapy to control pain.96 (See section on 
interventional procedures)
Costopleural syndrome
Mesothelioma is typically present with chest pain which 
may be pleuritic, lateralized, dull or diffuse. It typically 
progresses relentlessly during the course of mesothelioma 
and is often difficult to control. In mesothelioma this 
syndrome is referred to as a ‘costopleural syndrome’. 
The pain frequently has neuropathic components due 
to entrapment of intercostal thoracic, autonomic or 
brachial plexus nerves.97
Percutaneous cervical cordotomy has been 
proven to provide relief of pain in patients 
with costopleural  syndrome.97 This procedure 
interrupts the spinothalamic tract at C1/2 causing 
a contralateral loss of pain perception below the 
level of the lesion.98 Complications of cordotomy 
include thermo-anesthesia, troublesome dysesthesia 
and persisting motor weakness. One study reported 
a reduction in pain in 83% of patients following 
this procedure and 38% were able to stop opiate 
completely99 (See section on interventional 
procedures).
Liver metastases
Metastases to liver frequently cause right upper 
quadrant abdominal pain. This pain is secondary 
to stretching of the liver capsule either due to liver 
enlargement which may be secondary to metastatic 
lesions or hemorrhage into the liver from a metastatic 
deposit resulting in pain. Diaphragmatic irritation 
may result in referred pain to the ipsilateral shoulder. 
Analgesic options for this include corticosteroids to 
reduce edema, swelling and inflammation.
Brain metastases
Brain metastases from NSCLC occurs in approxi-
mately 33% of patients,100 whilst 10% of patients 
with SCLC present with brain metastases at the time 
of diagnosis. It is reported that 50% of patients with 
SCLC have brain metastases at 2 years.101 Treatment 
of pain involves reducing cerebral edema if present, 
with a corticosteroid (Dexamethasone). Alternatively 
headaches can be managed with radiotherapy. Other 
options for treating brain metastases include surgical 
resection, stereotactic radiosurgery, or chemotherapy.
Malignant pleural effusions
A malignant pleural effusion can also be a source of 
pain, in addition to causing symptoms of dyspnoea and 
cough. Thoracocentesis is recommended for symptom 
relief and pleurodesis should be performed should the 
pleural effusion recur after thoracocentesis. There are 
several pleurodesis agents including talc, tetracycline 
and bleomycin.102 Drainage of a symptomatic pleural 
effusion may not always relieve pain especially 
if there is parenchymal or pleural disease present. 
Therefore a thorough pain assessment is required 
after thoracocentesis.
Hypertrophic pulmonary  
osteo-arthropathy
Hypertrophic pulmonary osteo-arthropathy is defined 
by the presence of clubbing and periosteal proliferation 
of the tubular bones associated with lung cancer or 
other lung disease. It typically causes a symmetrical 
painful arthropathy affecting the ankles, knees, wrists 
and elbows. It will improve if the tumor is resected 
however in advanced lung cancer nonsteroidal anti-
inflammatory drugs (NSAIDs) or bisphosphonates 
are mainstay of treatment.103
Spinal cord stimulation
Spinal cord stimulation (SCS) has been used for 
treatment of intractable cancer pain. It has been 
estimated that up to 40% of chronic cancer pain has a 
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neuropathic component, a type of pain that responds 
favorably to spinal cord stimulation.104 Spinal cord 
stimulation is based on the principle enunciated in the 
‘gate-control theory’ of pain proposed by Melzacke 
and Wall in 1965 which postulated that the spinal 
cord stimulation analgesia stimulates large diameter 
afferent fibres.105 This stimulation in effect ‘closes the 
gate’ to pain transmission. It is thought that spinal cord 
stimulation blocks the pain by stimulating the dorsal 
columns which may inhibit transmission through the 
pain conducting spinothalamic tract as well as increase 
activity in descending anti-nociceptive pathways.106,107 
One study has found spinal cord stimulation to provide 
an effective alternative treatment option for select 
patients suffering from cancer related chest wall pain 
who have failed conservative treatment.108
Radiotherapy
Radiotherapy (RT) is well established in the palliative 
treatment of lung cancer. Indeed, 40%–50% of lung 
cancer patients receive radiotherapy, and, in 90% of 
these patients, the intent is palliative.109,110 The main 
indications for RT are cough, haemoptysis, pain, 
dyspnoea and airway obstruction.111–113 As with any 
treatment, it is vital that the treating radiation oncologist 
weighs up the pros and cons of treatment and discusses 
these with the patient so that the patient can come to an 
informed decision regarding their treatment.
Several studies have compared various dose and 
fractionation schedules in NSCLC. However, despite 
this, there is no real consensus on the optimal regime. 
This is due to the fact that reliable cancer therapies 
(RCTs) that have looked at this have reported 
contradictory results.113–125
A Cochrane review in 2006 looked at palliative 
radiotherapy regimes for NSCLC.126 Fourteen random-
ized controlled trials were identified. All 13 studies that 
investigated symptoms reported that major thoracic 
symptoms improved following RT. While there was 
no strong evidence to suggest that a higher dose was 
associated with better or longer lasting palliation, 
there did appear to be a modest survival advantage to 
higher doses of radiation in those patients who were 
performance status 0 or 1. However, higher doses of 
radiation were noted to be associated with more acute 
side effects, particularly radiation esophagitis and this 
should always be considered when prescribing a higher 
dose such as 36 Gray in 12 fractions.
From the larger studies that have investigated the 
response rate to pain from thoracic RT, this seems to be 
in the region of 50%–80%.127 Although endobronchial 
brachytherapy has been used to palliate symptoms 
such as cough, haemoptysis and dyspnoea, it has not 
been looked at in terms of pain palliation and so has 
not been covered in this review.128,129 There is little 
data on the effectiveness and safety of re-irradiation 
for locally recurrent NSCLC. However, review article 
by Jemeric et al concluded that, in selected patients, 
chest re-irradiation appears to be feasible, safe and 
effective at relieving symptoms associated with 
recurrence.130
One study discussed the pros and cons of 39 Gy in 
13 fractions with 17 Gy in 2 fractions with patients 
who met the eligibility criteria for the Medical 
Research Council (MRC) study which compared 
these two regimes.131 Of the 92 patients enrolled, 55% 
chose the longer schedule due to longer survival and 
better control rate. The shorter regime was chosen due 
to shorter treatment time, cost and better symptom 
control. All patients were satisfied with being involved 
in the decision-making process. Surprisingly, 56% of 
those choosing the shorter regime had their treatment 
altered by their treating oncologist whereas only 4% 
who chose the longer regime had their treatment 
altered by their oncologist. This reflects the biases of 
the treating oncologists.
Most data looking at pain palliation in lung tumors 
has focused on NSCLC rather than SCLC. This is 
because SCLC is typically a central disease that causes 
dyspnoea, pneumonia due to obstruction, and superior 
vena cava obstruction (SVCO) more commonly 
than pain. In addition, SCLC is a chemosensitive 
disease and so, in the palliative setting, RT is more 
commonly reserved for patients who have either had 
a poor response to chemotherapy or are too frail to 
be considered for systemic therapy. In these patients, 
given the very poor survival rate, short fractionation 
schedules are recommended.
The Royal College of Radiologists recommend 
either a single 10 Gy fraction of RT or 17 Gy in 
two fractions for patients with moderate to poor 
performance status.132 These recommendations 
are based on the three Medical Research Council 
studies that were performed in the 1980’s and early 
1990’s.117,118,120 If 17 Gy in two fractions is favored, 
consideration must be given to spinal cord shielding 
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as radiation myelopathy was suspected in one patient 
in MRC 1991 and confirmed in one patient in MRC 
1992, both of whom received 17 Gy in two fractions. 
In view of the third MRC trial, those patients with 
good PS (0–1) should be considered for a higher 
fractionated dose such as 36 Gy in 12 fractions.
Radiotherapy has an important role to play in the 
palliation of pain in advanced lung cancer. Although 
there is not widespread agreement on the dose and 
fractionation schedules that should be used, there is 
general agreement that short fractionations should 
be considered for all patients with poor performance 
status. For those patients with advanced lung cancer 
and good performance status, consideration should 
be given to higher doses of fractionated radiotherapy 
given the possible survival advantage. However, 
this must be weighed against the increased toxicity 
of such regimens, in particular radiation esophagitis. 
Oncologists should be aware of their own personal 
biases when discussing different RT regimes with 
their patients.
Intractable pain
In the event that pain cannot be controlled, particularly 
if dose escalation of opioids is limited by systemic 
side effects, epidural or intra-thecal analgesia may be 
considered (see section on interventional procedures). 
Spinal opioids can be used in combination with local 
anesthetic or Clonidine in patients who have intolerable 
adverse effects with systemically administered 
opioids.133 This route of opioid administration is 
only performed by specialists who are skilled in the 
procedure and its monitoring. It is most useful in 
intractable pain occurring to the lower part of the 
body and involves the placement of a delivery system 
consisting of a catheter and a port or a pump that can 
be internalized for prolonged use.
Intra-ventricular opioids are useful for recalcitrant 
pain due to tumors affecting the brachial plexus. 
It requires the placement of a ventricular catheter 
connected to a subcutaneous reservoir that can be 
accessed.134
Neural blockade (see section on interventional 
procedures) can sometimes control intractable pain 
when all other therapies fail. Temporary block with a 
local anesthetic is initially applied prior to a planned 
neurolytic block to assess side effects as well as to 
predict the likely outcome.134
Additional Approaches
Patients with lung cancer experience multiple 
symptoms both from complications of the cancer itself 
in addition to cancer related treatments. Dyspnoea is 
a commonly reported symptom in lung cancer and 
it has been noted that the incidence of dyspnoea is 
higher when pain and anxiety are high.135,136 It is 
therefore necessary to treat dyspnoea in an holistic 
manner addressing pain control in addition to ensuring 
adequate pharmacological treatment with inhaled 
bronchodilators, corticosteroids, anxiolytics, oxygen 
therapy, and opioids. Emphasis must be placed 
on the benefit of non-pharmacological therapies 
for dyspnoea which include breathing exercises, 
relaxation techniques and psychological support. A 
similar approach must be taken with all symptoms 
in patients with lung cancer, which may be directly 
related to the cancer or due to other co-morbidities.
Psychological distress is also related to the 
symptoms of patients with cancer and consequently 
psychological support and care must be integral to 
the patient’s treatment.4 Untreated psychological 
distress may exacerbate pain or other symptoms. 
It is therefore important to ensure that patients 
have access to a counseling and spiritual support. 
Psychological therapies are all primarily aimed at 
promoting relaxation, controlling stress and anxiety 
and improved coping mechanisms and adjustment.137
Complementary therapies are used as adjuncts 
to current evidence based management. They are 
supportive measures that assist in symptom control, 
enhance well-being, and contribute to overall patient 
care.138 Complementary therapy has been integrated 
into the management of patients with cancer and it 
has been noted that the uptake of complementary and 
alternative medicine increases with advancing disease, 
unmet patient needs, and helplessness.139 There is a 
minimal evidence supporting the use of complementary 
and alternative therapies.140 It is important to evaluate 
herbal and other dietary products for side effects and 
potential interactions with chemotherapy and other 
medication.
Acupuncture has been shown to be of benefit to 
patients with lung cancer and can be used concurrently 
for neuropathic pain, nausea and vomiting, smoking 
cessation and for pain.141
Non-pharmacological methods to manage pain 
include cutaneous stimulation techniques (heat and 
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cold applications) acupuncture, psychosocial methods 
of care, holistic management and pastoral care.
conclusion
In conclusion, an active multidisciplinary approach 
is required to manage pain in patients with advanced 
lung cancer. Pain can be multifactorial in this patient 
population and therefore may require several different 
analgesics along with specialist palliative general and 
pain management. As lung cancer continues to be 
both prevalent and carry a high symptom burden, the 
importance of optimum pain management increases.
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